0TDF.LSE Roche Holding AG
- Market cap
- -
- P/E
- 29.1x
- P/B
- -
- ROE
- -
- Dividend yield
- 1.99%
- Fundamental score
- -
Is 0TDF.LSE undervalued?
Graham numberThe Graham number of Roche Holding AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Roche Holding AG fundamental analysis
No fundamental analysis for Roche Holding AG yet.
Roche Holding AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various dise…
Full company profileFinancial statements of Roche Holding AG are not available yet.
Roche Holding AG dividends
Roche Holding AG has not paid dividends in the last 4 fiscal years.
Who owns Roche Holding AG
- Insiders 0.00%
- Institutions 0.40%
- Public & others 99.60%
- Free float 5.79B
Roche Holding AG company profile
- Company name
- Roche Holding AG
- Ticker
- 0TDF.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 103,249
- Fiscal year end
- December
- Address
- Grenzacherstrasse 124, Basel, Switzerland, 4070
- Phone
- 41 61 688 88 80
- Website
- roche.com
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Roche Holding AG management
10- Dr. Severin Schwan Ph.D.Executive Chairman · born 1967
- Dr. Thomas SchineckerGroup Chief Executive Officer · born 1975
- Dr. Alan HippeChief Financial Officer · born 1967
- Ms. Wafaa MamilliChief Digital & Technology Officer · born 1967
- Dr. Bruno EschliHead of Investor Relations
- Ms. Claudia BockstiegelGeneral Counsel · born 1964
- Dr. Nina Schwab-HautzingerHead of Group Communications · born 1975
- Ms. Maria Cristina A. WilburChief People Officer · born 1967
- Dr. Nicolas DunantHead of Group Media Relations
- Mr. Boris L. ZaitraHead of Corporate Business Development · born 1972